⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
IL-21R Blockade
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-03 — IL-21R blockade reduces inflammation and atherosclerosis in LDL receptor deficient mice.: Preclinical study in Ldlr-/- mice: anti-IL-21R monoclonal antibody reduced atherosclerotic plaque area and macrophage content in young mice and lowered residual inflammation in aged mice with established plaques, via expansion of atheroprotective Tregs, reduction of pro-inflammatory monocytes, and disruption of age-associated Tfh–B-cell dynamics; human plaque scRNAseq confirmed IL-21R expression on Tregs (target-engagement rationale, mechanism-plausible). [animal-model] (novelty: 3)
Open questions
Related
Contributing findings
IL-21R blockade reduces inflammation and atherosclerosis in LDL receptor deficient mice.
03-sep-2026
novelty 3
per-area 3
strengthens